CTCF and fragile X syndrome: While CTCF binding has been seen in some cells from unaffected individuals and is missing from the same cell type in affected individuals [69,70], demethylation of the FMR1 promoter in FXS lymphoblastoid cells by 5-aza-dC treatment did not restore CTCF binding.